United Therapeutics Corporation/ US91307C1027 /
| 2024-04-24 10:00:00 PM | Chg. +2.5300 | Volume | Bid1:00:00 PM | Ask1:00:00 PM | Market Capitalization | Dividend Y. | P/E Ratio |
|---|---|---|---|---|---|---|---|
| 237.0000USD | +1.08% | 671,048 Turnover: 67.78 mill. |
215.0000Bid Size: 100 | 243.0800Ask Size: 200 | 11.15 bill.USD | - | 11.26 |
Assets
|
2019 US GAAP in mill. USD |
2020 US GAAP in mill. USD |
2021 US GAAP in mill. USD |
2022 US GAAP in mill. USD |
2023 US GAAP in mill. USD |
||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Property and Equipment | 738.5000 | 731.6000 | 780.9000 | 861.5000 | 1,045.4000 | ||||||
| Intangible Assets | - | - | - | - | - | ||||||
| Long-Term Investments | 767.5000 | 1,149.6000 | 1,649.9000 | 1,316.2000 | 1,909.8000 | ||||||
| Fixed Assets | 2,048.9000 | 2,447.8000 | 2,845.5000 | 2,664.2000 | 3,616 | ||||||
| Inventories | 93.4000 | 86.5000 | 93.8000 | 102 | 111.8000 | ||||||
| Accounts Receivable | 151.4000 | 157.4000 | 198.7000 | 220.4000 | 278.9000 | ||||||
| Cash and Cash Equivalents | 738.4000 | 738.7000 | 894.8000 | 961.2000 | 1,207.7000 | ||||||
| Current Assets | 1,864.5000 | 2,167.2000 | 2,323.6000 | 3,380.3000 | 3,551 | ||||||
| Total Assets | 3,913.4000 | 4,615 | 5,169.1000 | 6,044.5000 | 7,167 | ||||||
Liabilities
|
2019 US GAAP in mill. USD |
2020 US GAAP in mill. USD |
2021 US GAAP in mill. USD |
2022 US GAAP in mill. USD |
2023 US GAAP in mill. USD |
||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Accounts Payable | - | - | - | - | - | ||||||
| Long-term debt | 600 | 800 | 800 | 800 | 300 | ||||||
| Liabilities to Banks | 600 | - | - | - | - | ||||||
| Provisions | - | - | - | - | - | ||||||
| Liabilities | 1,133 | 1,219.8000 | 1,210.2000 | 1,247.8000 | 1,182.2000 | ||||||
| Share Capital | .7000 | .7000 | .7000 | .7000 | .7000 | ||||||
| Total Equity | 2,780.4000 | 3,395.2000 | 3,958.9000 | 4,796.7000 | 5,984.8000 | ||||||
| Minority Interests | - | - | - | - | - | ||||||
| Total liabilities equity | 3,913.4000 | 4,615 | 5,169.1000 | 6,044.5000 | 7,167 | ||||||
Income Statement
|
2019 US GAAP in mill. USD |
2020 US GAAP in mill. USD |
2021 US GAAP in mill. USD |
2022 US GAAP in mill. USD |
2023 US GAAP in mill. USD |
||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenues | 1,448.8000 | 1,483.3000 | 1,685.5000 | 1,936.3000 | 2,327.5000 | ||||||
| Depreciation (total) | - | - | - | - | - | ||||||
| Operating Result | -187.6000 | 593.6000 | 555.9000 | 979.7000 | 1,184.9000 | ||||||
| Interest Income | 0.0000 | 5.1000 | -1.9000 | 12.8000 | 103.4000 | ||||||
| Income Before Taxes | -165 | 638.9000 | 593.9000 | 950.6000 | 1,274.3000 | ||||||
| Income Taxes | 60.5000 | -124.1000 | -118.1000 | -223.3000 | -289.5000 | ||||||
| Minority Interests Profit | - | - | - | - | - | ||||||
| Net Income | -104.5000 | 514.8000 | 475.8000 | 727.3000 | 984.8000 | ||||||
Per Share
Cash Flow
|
2019 US GAAP in mill. USD |
2020 US GAAP in mill. USD |
2021 US GAAP in mill. USD |
2022 US GAAP in mill. USD |
2023 US GAAP in mill. USD |
||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash Flow from Operating Activities | -206.6000 | 755.7000 | 598.2000 | 802.5000 | 978 | ||||||
| Cash Flow from Investing Activities | -335.4000 | -738.5000 | -486.9000 | -811.5000 | -719.6000 | ||||||
| Cash Flow from Financing | 611.2000 | -16.9000 | 44.8000 | 75.4000 | -11.9000 | ||||||
| Decrease / Increase in Cash | 69.2000 | .3000 | 156.1000 | 66.4000 | 246.5000 | ||||||
| Employees | 920 | - | - | - | - | ||||||
